These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

78 related articles for article (PubMed ID: 16883681)

  • 1. Tumor growth parameters of in-vivo human breast carcinoma: a proposed mathematical model for tumor growth kinetics.
    González MJ; Herrera FL; Miranda-Massari JM; Guzmán AM; Riordan NH; Ricart CM
    P R Health Sci J; 2006 Mar; 25(1):71-3. PubMed ID: 16883681
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A mathematical model for the effects of HER2 overexpression on cell proliferation in breast cancer.
    Eladdadi A; Isaacson D
    Bull Math Biol; 2008 Aug; 70(6):1707-29. PubMed ID: 18648887
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A microenvironment based model of antimitotic therapy of Gompertzian tumor growth.
    Kozusko F; Bourdeau M; Bajzer Z; Dingli D
    Bull Math Biol; 2007 Jul; 69(5):1691-708. PubMed ID: 17577604
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis.
    Yee AJ; Akens M; Yang BL; Finkelstein J; Zheng PS; Deng Z; Yang B
    Breast Cancer Res; 2007; 9(4):R47. PubMed ID: 17662123
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Silencing of transforming growth factor-beta1 in situ by RNA interference for breast cancer: implications for proliferation and migration in vitro and metastasis in vivo.
    Moore LD; Isayeva T; Siegal GP; Ponnazhagan S
    Clin Cancer Res; 2008 Aug; 14(15):4961-70. PubMed ID: 18676771
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phenomenological modeling of tumor diameter growth based on a mixed effects model.
    Bastogne T; Samson A; Vallois P; Wantz-Mézières S; Pinel S; Bechet D; Barberi-Heyob M
    J Theor Biol; 2010 Feb; 262(3):544-52. PubMed ID: 19835891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumor-specific RNAi targeting eIF4E suppresses tumor growth, induces apoptosis and enhances cisplatin cytotoxicity in human breast carcinoma cells.
    Dong K; Wang R; Wang X; Lin F; Shen JJ; Gao P; Zhang HZ
    Breast Cancer Res Treat; 2009 Feb; 113(3):443-56. PubMed ID: 18327707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Primary lung cancer vs metastatic breast cancer: a probabilistic approach.
    Vollmer RT
    Am J Clin Pathol; 2009 Sep; 132(3):391-5. PubMed ID: 19687315
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Human bone marrow stromal cells enhance breast cancer cell growth rates in a cell line-dependent manner when evaluated in 3D tumor environments.
    Sasser AK; Mundy BL; Smith KM; Studebaker AW; Axel AE; Haidet AM; Fernandez SA; Hall BM
    Cancer Lett; 2007 Sep; 254(2):255-64. PubMed ID: 17467167
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [A simplified model for kinetics of a tumor cells' population].
    Gut R; Zharinov GM; Iakubov E
    Vopr Onkol; 2009; 55(1):83-8. PubMed ID: 19435206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Growth suppression of MCF-7 cancer cell-derived xenografts in nude mice by caveolin-1.
    Wu P; Wang X; Li F; Qi B; Zhu H; Liu S; Cui Y; Chen J
    Biochem Biophys Res Commun; 2008 Nov; 376(1):215-20. PubMed ID: 18778685
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Continuous administration of the somatostatin structural derivative /TT-232/ by subcutaneously implanted osmotic pump improves the efficacy and potency of antitumor therapy in different mouse and human tumor models.
    Tejeda M; Gaal D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri GY
    Anticancer Res; 2008; 28(5A):2769-74. PubMed ID: 19035308
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Estrogenic regulation of host immunity against an estrogen receptor-negative human breast cancer.
    Curran EM; Judy BM; Duru NA; Wang HQ; Vergara LA; Lubahn DB; Estes DM
    Clin Cancer Res; 2006 Oct; 12(19):5641-7. PubMed ID: 17000652
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Mathematical modelling of liver regeneration after intoxication with CCl(4).
    Höhme S; Hengstler JG; Brulport M; Schäfer M; Bauer A; Gebhardt R; Drasdo D
    Chem Biol Interact; 2007 May; 168(1):74-93. PubMed ID: 17442287
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A novel bioluminescent tumor model of human renal cancer cell lines: an in vitro and in vivo characterization.
    Peter C; Kielstein JT; Clarke-Katzenberg R; Adams MC; Pitsiouni M; Kambham N; Karimi MA; Kengatharan KM; Cooke JP
    J Urol; 2007 Jun; 177(6):2342-6. PubMed ID: 17509355
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Broad antitumor activity in breast cancer xenografts by motesanib, a highly selective, oral inhibitor of vascular endothelial growth factor, platelet-derived growth factor, and Kit receptors.
    Coxon A; Bush T; Saffran D; Kaufman S; Belmontes B; Rex K; Hughes P; Caenepeel S; Rottman JB; Tasker A; Patel V; Kendall R; Radinsky R; Polverino A
    Clin Cancer Res; 2009 Jan; 15(1):110-8. PubMed ID: 19118038
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characterization of primary breast carcinomas grown in three-dimensional cultures.
    Becker JL; Blanchard DK
    J Surg Res; 2007 Oct; 142(2):256-62. PubMed ID: 17727885
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Quantifying in vitro growth and metabolism kinetics of human mesenchymal stem cells using a mathematical model.
    Higuera G; Schop D; Janssen F; van Dijkhuizen-Radersma R; van Boxtel T; van Blitterswijk CA
    Tissue Eng Part A; 2009 Sep; 15(9):2653-63. PubMed ID: 19207045
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mathematical modeling of liver metastases tumour growth and control with radiotherapy.
    Campbell A; Sivakumaran T; Davidson M; Lock M; Wong E
    Phys Med Biol; 2008 Dec; 53(24):7225-39. PubMed ID: 19047765
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A comparison of the tumor growth inhibitory effect of intermittent and continuous administration of the somatostatin structural derivative TT-232 in various human tumor models.
    Tejeda M; Gaál D; Hullán L; Csuka O; Schwab R; Szokoloczi O; Kéri G
    Anticancer Res; 2006; 26(4B):3011-5. PubMed ID: 16886628
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.